Conventional fractionation should not be the standard of care for T2 glottic cancer

• Main Authors: Lynne M. Dixon, Catriona M. Douglas, Shazril Imran Shaukat, Kate Garcez, Lip Wai Lee, Andrew J. Sykes, David Thomson, Nicholas J. Slevin
• Format: Article
• Language: English
• Published: BMC 2017-11-01
• Series: Radiation Oncology
• Subjects: T2 Glottic; Biologically effective dose; Hypofractionation; Local control; Radiotherapy
• Online Access: http://link.springer.com/article/10.1186/s13014-017-0915-8

Abstract Background The aim of this study was to report outcomes and late toxicity following hypofractionated accelerated radiotherapy for T2 glottic cancers. We highlight the importance of hypofractionated treatments with shorter overall treatment times, in improving outcomes for T2 glottic cancers. We also compare the biologically effective dose of hypofractionated regimes, with conventional fractionation. Methods One hundred twelve patients with T2 glottic cancer were treated between January 1999 and December 2005. All patients were prescribed a hypofractionated accelerated radiotherapy dose of 52.5 Gray in 3.28 Gray per fraction, delivered over 22 days. Radiobiological calculations were used to assess the relationship of fraction size and overall treatment time on local control outcomes and late toxicity. Results The 5-year overall survival was 67%, the 5-year local control was 82%, and the 5-year disease-specific survival was 90%. The respective 5-year local control for T2a and T2b disease was 88.8 and 70.8% (p = 0.032). Severe late toxicity occurred in two patients (1.8%). Radiobiological calculations showed an increase in local control of nearly 12%, with a 10 Gray increase in biologically effective dose. Conclusion This study has demonstrated that accelerated hypofractionated regimes have improved local control and similar late toxicity compared with conventional fractionation schedules. This supports the use of hypofractionated regimes as the standard of care for early glottic laryngeal cancers.